The STEP 1 trial, published in the New England Journal of Medicine in 2021, showed that participants taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group
Originally developed as a treatment for type 2 diabetes, Semaglutide, a GLP-1 agonist (glucagon-like peptide-1), quickly gained attention for its weight loss benefits
The discovery of the G-proteincoupled estrogen receptor (GPER1) in the early 2000s provided insight into these non-genomic mechanisms (Nilsson et al., 2011)
Clinical trials testing these medications are also underway, but we hope our findings will help shape more targeted clinical trials in the future. Advertisement Advertisement Two Cleveland Clinic neurologists review biomarker advances, targeted therapies and unresolved clinical challenges An expert talks through the benefits, limits and unresolved questions of an evolving technology How were efficiently educating patients and care partners about treatment goals, logistics, risks and benefits Large NIH-funded investigation is exploring this understudied phenomenon Genomic study lays groundwork for insights into potential biomarkers and therapeutic strategies Proteins related to altered immune response are potential biomarkers of the rare AD variant Alzheimers studies delve into sex-related variances in the expression of the disease Validated scale provides a method for understanding how lifestyle may protect against Alzheimer's
